PCM
LCTX icon

Prelude Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Prelude Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,942
Closed -$23.6K – 1399
2026
Q1 		$23.6K Buy
+14,942
New +$25.2K ﹤0.01% 1157
2023
Q2 		– Sell
-16,688
Closed -$25K – 1252
2023
Q1 		$25K Buy
+16,688
New +$23.3K ﹤0.01% 1037
2022
Q4 		– Sell
-11,465
Closed -$13K – 1481
2022
Q3 		$13K Buy
+11,465
New +$16.8K ﹤0.01% 1295
2021
Q2 		– Sell
-17,529
Closed -$41K – 1822
2021
Q1 		$41K Buy
+17,529
New +$42.1K ﹤0.01% 1468
2017
Q4 		– Sell
-4,115
Closed -$10K – 1550
2017
Q3 		$10K Buy
4,115
+1,257
+44% +$3.12K ﹤0.01% 1434
2017
Q2 		$8K Sell
2,858
-31,089
-92% -$86.9K ﹤0.01% 1426
2017
Q1 		$102K Buy
33,947
+28,918
+575% +$82.1K 0.01% 776
2016
Q4 		$16K Buy
+5,029
New +$15.4K ﹤0.01% 1332
2014
Q3 		– Sell
-9,498
Closed -$23K – 1994
2014
Q2 		$23K Buy
9,498
+929
+11% +$2.1K ﹤0.01% 1691
2014
Q1 		$23K Buy
+8,569
New +$25.2K ﹤0.01% 1643

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Prelude Capital Management's LCTX Position: Q2 2026 in Review

Prelude Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 14,942 shares — an estimated $23.6K sold.

Prelude Capital Management first reported a position in LCTX in Q1 2014 and held it in 10 quarters. The position peaked at $102K in Q1 2017. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Prelude Capital Management reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 14,942 Lineage Cell Therapeutics shares in Q2 2026, an estimated $23.6K.
  • Prelude Capital Management first reported a position in Lineage Cell Therapeutics in Q1 2014 and held it in 10 quarters.
  • Prelude Capital Management's Lineage Cell Therapeutics position peaked at $102K in Q1 2017.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.